Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246625 | 0.99 | BRAF (0.42) | MAP2K4BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL298320 | 0.90 | CYP2C9 (0.48) | MAP2K4BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL10246332 | 0.90 | PAK1 (0.41) | MAP2K4BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL298879 | 0.90 | CYP2C9 (0.49) | MAP2K4BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL298881 | 0.87 | CAMKK2 (0.48) | MAP2K4BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL10246345 | 0.86 | CYP2C19 (0.43) | MAP2K4BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL298205 | 0.86 | CAMKK2 (0.49) | BRAFPAK1CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL298226 | 0.82 | PAK1 (0.51) | BRAFPAK1CYP2C19CYP3A4 | |
| SCHEMBL7875664 | 0.81 | RIPK1 (0.46) | BRAFPAK1RIPK1 | |
| SCHEMBL298370 | 0.81 | CYP2C19 (0.49) | MAP2K4BRAFPAK1CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | MAP2K4 118/4885BRAF 1/4885PAK1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.